(Q33726204)

28 July 2017

1 reference

title

Comprehensive pharmacology and clinical efficacy of aromatase inhibitors (English)

1 reference

28 July 2017

1 reference

0 references

Njar VC

1

1 reference

28 July 2017

Brodie AM

series ordinal

2

1 reference

28 July 2017

publication date

1 August 1999

1 reference

28 July 2017

1 reference

28 July 2017

volume

58

1 reference

28 July 2017

issue

2

1 reference

28 July 2017

page(s)

233-255

1 reference

Adrenal suppression with aminoglutethimide. II. Differential effects of aminoglutethimide on plasma androstenedione and estrogen levels

28 July 2017

cites work

1 reference

12 December 2020

Second generation aromatase inhibitor--4-hydroxyandrostenedione

1 reference

12 December 2020

1 reference

12 December 2020

ARIMIDEX: a potent and selective aromatase inhibitor for the treatment of advanced breast cancer

1 reference

12 December 2020

Plasma Precursors of Estrogen. II. Correlation of the Extent of Conversion of Plasma Androstenedione to Estrone with Age1

1 reference

12 December 2020

Expression of aromatase protein and messenger ribonucleic acid in tumor epithelial cells and evidence of functional significance of locally produced estrogen in human breast cancers

1 reference

12 December 2020

Biochemical and molecular aspects of aromatase

1 reference

12 December 2020

Aromatase inhibitors and their potential clinical significance

1 reference

12 December 2020

Aminoglutethimide Inhibits Extraglandular Estrogen Production in Postmenopausal Women with Breast Carcinoma*

1 reference

12 December 2020

Mechanism and inhibition of cytochrome P-450 aromatase

1 reference

12 December 2020

Treatment of severe postmenopausal endometriosis with an aromatase inhibitor

1 reference

12 December 2020

A sensitive assay for measurement of plasma estrone sulphate in patients on treatment with aromatase inhibitors

1 reference

12 December 2020

Aminoglutethimide (Elipten-Ciba) as an inhibitor of adrenal steroidogenesis: mechanism of action and therapeutic trial.

1 reference

12 December 2020

CGS 16949A, a new nonsteroidal aromatase inhibitor: effects on hormone-dependent and -independent tumors in vivo

1 reference

12 December 2020

Effects of aromatase inhibitors, aminoglutethimide, and 4-hydroxyandrostenedione on cyclic rats and rats with 7,12-dimethylbenz(a)anthracene-induced mammary tumors

1 reference

12 December 2020

A study of fadrozole, a new aromatase inhibitor, in postmenopausal women with advanced metastatic breast cancer

1 reference

12 December 2020

Chemopreventive effects of the aromatase inhibitors vorozole (R-83842) and 4-hydroxyandrostenedione in the methylnitrosourea (MNU)-induced mammary tumor model in Sprague-Dawley rats

1 reference

12 December 2020

Mechanisms of the actions of aromatase inhibitors 4-hydroxyandrostenedione, fadrozole, and aminoglutethimide on aromatase in JEG-3 cell culture

1 reference

12 December 2020

Plasma estrogen suppression with aromatase inhibitors evaluated by a novel, sensitive assay for estrone sulphate

1 reference

12 December 2020

First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88

1 reference

12 December 2020

Evidence that corticosterone is not an obligatory intermediate in aldosterone biosynthesis in the rat adrenal

1 reference

12 December 2020

Aromatase activity in normal breast and breast tumor tissues: in vivo and in vitro studies

1 reference

12 December 2020

Lack of evidence for aromatase in human prostatic tissues: effects of 4-hydroxyandrostenedione and other inhibitors on androgen metabolism

1 reference

12 December 2020

A phase I trial of CGS 16949A. A new aromatase inhibitor

1 reference

12 December 2020

Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancer

1 reference

12 December 2020

Endocrine treatment of breast cancer in women

1 reference

12 December 2020

Aromatase activity in the breast and other peripheral tissues and its therapeutic regulation

1 reference

12 December 2020

Endocrine changes with the aromatase inhibitor fadrozole hydrochloride in breast cancer

1 reference

12 December 2020

Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study.

1 reference

12 December 2020

Growth suppression of MCF-7 human breast cancer cells by aromatase inhibitors: a new system for aromatase inhibitor screening

1 reference

12 December 2020

Stromal spindle cells contain aromatase in human breast tumors

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione in patients with postmenopausal breast cancer

1 reference

12 December 2020

Aromatization of androgens by muscle and adipose tissue in vivo

1 reference

12 December 2020

Steroid Dynamics under Steady-State Conditions

1 reference

12 December 2020

Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women

1 reference

12 December 2020

The new aromatase inhibitor CGS-16949A suppresses aldosterone and cortisol production by human adrenal cells in vitro

1 reference

12 December 2020

Open dose-finding study of a new potent and selective nonsteroidal aromatase inhibitor, CGS 20 267, in healthy male subjects

1 reference

12 December 2020

Comparative effects of the aromatase inhibitor R76713 and of its enantiomers R83839 and R83842 on steroid biosynthesis in vitro and in vivo

1 reference

12 December 2020

The steroidal antiestrogen ICI 182,780 is an inhibitor of cellular aromatase activity

1 reference

12 December 2020

The P450 superfamily: update on new sequences, gene mapping, and recommended nomenclature

1 reference

12 December 2020

In vitro and in vivo studies with aromatase inhibitor 4-hydroxy-androstenedione

1 reference

12 December 2020

A reassessment of the role of breast tumor aromatization

1 reference

12 December 2020

Significance of aromatase activity in human breast cancer

1 reference

12 December 2020

4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer

1 reference

12 December 2020

A new nude mouse model for postmenopausal breast cancer using MCF-7 cells transfected with the human aromatase gene

1 reference

12 December 2020

Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.

1 reference

12 December 2020

Time-dependent inhibition of aromatase in trophoblastic tumor cells in tissue culture

1 reference

12 December 2020

1 reference

12 December 2020

In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer.

1 reference

12 December 2020

Effect of aromatase inhibitors on growth of mammary tumors in a nude mouse model

1 reference

12 December 2020

Effect of the irreversible aromatase inhibitor FCE 24304 on DMBA-induced mammary tumors in ovariectomized rats treated with testosterone

1 reference

12 December 2020

Analogues of aminoglutethimide: selective inhibition of aromatase

1 reference

12 December 2020

The preclinical pharmacology of "Arimidex" (anastrozole; ZD1033)--a potent, selective aromatase inhibitor

1 reference

12 December 2020

Weight changes in women with metastatic breast cancer treated with megestrol acetate: a comparison of standard versus high-dose therapy.

1 reference

12 December 2020

A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients

1 reference

12 December 2020

Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer

1 reference

12 December 2020

Inhibition of peripheral aromatization by aromatase inhibitors, 4-hydroxy- and 4-acetoxy-androstene-3,17-dione

1 reference

12 December 2020

Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration

1 reference

12 December 2020

Detection of aromatase and keratinocyte growth factor expression in breast tumors using reverse transcription-polymerase chain reaction

1 reference

12 December 2020

4-Aminoandrostenedione derivatives: a novel class of irreversible aromatase inhibitors. Comparison with FCE 24304 and 4-hydroxyandrostenedione

1 reference

12 December 2020

Hormonal therapy in cancer of the breast 16. The effect of Delta 1-testololactone on clinical course and hormonal excretion

1 reference

12 December 2020

Tissue-specific promoters regulate aromatase cytochrome P450 expression

1 reference

12 December 2020

Aminoglutethimide stimulates extra adrenal delta-4-androstenedione production

1 reference

12 December 2020

Aromatase in the human testis.

1 reference

12 December 2020

Aromatase inhibitors and breast cancer

1 reference

12 December 2020

Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group

1 reference

12 December 2020

Potency and selectivity of the non-steroidal aromatase inhibitor CGS 16949A in postmenopausal breast cancer patients

1 reference

12 December 2020

Emerging role of aromatase inhibitors in the treatment of breast cancer

1 reference

12 December 2020

Effect of aminoglutethimide on antipyrine, theophylline, and digitoxin disposition in breast cancer

1 reference

12 December 2020

Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: results of two randomized double blind controlled multiinstitutional trials

1 reference

12 December 2020

Concentration of endogenous oestradiol as related to oestradiol receptor sites in breast tumor cytosol

1 reference

12 December 2020

Pyridoglutethimide [3-ethyl-3-(4-pyridyl)-piperidine-2,6-dione], an analogue of aminoglutethimide. Metabolism and pharmacokinetics

1 reference

12 December 2020

Inhibition of aromatase with CGS 16949A in postmenopausal women

1 reference

12 December 2020

Human aromatase: cDNA cloning, Southern blot analysis, and assignment of the gene to chromosome 15.

1 reference

12 December 2020

Estrogen formation in stromal cells of adipose tissue of women: induction by glucocorticosteroids

1 reference

12 December 2020

Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer

1 reference

12 December 2020

Preliminary study of the treatment of advanced breast cancer in postmenopausal women with the aromatase inhibitor CGS 16949A

1 reference

12 December 2020

Biological effects of stable overexpression of aromatase in human hormone-dependent breast cancer cells

1 reference

12 December 2020

Aromatase Inhibitors III. Studies on the Antifertility Effect of 4-Acetoxy-4-androstene-3,17-dione1, 2, 3

1 reference

12 December 2020

Studies on the mechanism of estrogen biosynthesis. 8. The development of inhibitors of the enzyme system in human placenta

1 reference

12 December 2020

Utilization of oxygen and reduced nicotinamide adenine dinucleotide phosphate by human placental microsomes during aromatization of androstenedione

1 reference

12 December 2020

Hormonal Regulation of the Differentiation of Cultured Ovarian Granulosa Cells*

1 reference

12 December 2020

Antitumoral and endocrine effects of (+)-vorozole in rats bearing dimethylbenzanthracene-induced mammary tumors

1 reference

12 December 2020

Measurement of Aromatisation by a Urine Technique Suitable for the Evaluation of Aromatase Inhibitorsin Vivo

1 reference

12 December 2020

Distribution and regulation of aromatase activity in the rat hypothalamus and limbic system

1 reference

12 December 2020

Suicide enzyme inhibitors as potential drugs

1 reference

12 December 2020

In vitro and in vivo studies demonstrating potent and selective estrogen inhibition with the nonsteroidal aromatase inhibitor CGS 16949A.

1 reference

12 December 2020

Inhibition of aromatase in vitro and in vivo by aromatase inhibitors

1 reference

12 December 2020

Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: phase II report

1 reference

12 December 2020

Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated breast cancer patients: clinical and endocrine effects

1 reference

12 December 2020

New non-steroidal aromatase inhibitors: focus on R76713.

1 reference

12 December 2020

The stereospecific removal of a C-19 hydrogen atom in oestrogen biosynthesis

1 reference

12 December 2020

Conversion of 19-oxo[2 beta-2H]androgens into oestrogens by human placental aromatase. An unexpected stereochemical outcome

1 reference

12 December 2020

Exemestane experience in breast cancer treatment

1 reference

12 December 2020

The effects of aromatase inhibitors and antiestrogens in the nude mouse model

1 reference

12 December 2020

Immunocytochemical studies of aromatase in early and full-term human placental tissues: comparison with biochemical assays

1 reference

12 December 2020

Anastrozole. A review of its use in the management of postmenopausal women with advanced breast cancer

1 reference

12 December 2020

Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate

1 reference

12 December 2020

Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue

1 reference

12 December 2020

CGS 16949A, a new aromatase inhibitor in the treatment of breast cancer--a phase I study

1 reference

12 December 2020

Current perspectives on aromatase inhibitors in breast cancer

1 reference

12 December 2020

Effect of dose and hormones on tumor production in rats given emulsified 9, 10-dimethyl-1,2-benzanthracene intravenously.

1 reference

12 December 2020

Tamoxifen for the prevention of breast cancer. Important questions remain unanswered, and existing trials should continue

1 reference

12 December 2020

Alterations in the metabolism of oestrogens during treatment with aminoglutethimide in breast cancer patients. Preliminary findings

1 reference

12 December 2020

Aromatase enzyme catalysis is involved in the potent inhibition of estrogen biosynthesis caused by 4-acetoxy- and 4-hydroxy-4-androstene-3, 17-dione

1 reference

12 December 2020

Studies on the mechanism of estrogen biosynthesis in the rat ovary--I

1 reference

12 December 2020

A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer.

1 reference

12 December 2020

Oral 4-hydroxyandrostenedione, a new endocrine treatment for disseminated breast cancer

1 reference

12 December 2020

Inhibition of Peripheral Aromatization in Baboons by an Enzyme-Activated Aromatase Inhibitor (MDL 18,962)*

1 reference

12 December 2020

Aromatase in human breast carcinoma

1 reference

12 December 2020

Immunolocalization of aromatase and other steroidogenic enzymes in human breast disorders

1 reference

12 December 2020

In situ oestrone synthesis in normal breast and breast tumour tissues: effect of treatment with 4-hydroxyandrostenedione

1 reference

12 December 2020

Studies on estrogen biosynthesis using radioactive and stable isotopes

1 reference

12 December 2020

Aromatase inhibition with 4-OHAndrostenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer

1 reference

12 December 2020

The involvement of human placental microsomal cytochrome P-450 in aromatization

1 reference

12 December 2020

Inactivation of aromatase in vitro by 4-hydroxy-4-androstene-3,17-dione and 4-acetoxy-4-androstene-3,17-dione and sustained effects in vivo

1 reference

12 December 2020

Studies on the mechanism of estrogen biosynthesis. VI. The stereochemistry of hydrogen elimination at C-2 during aromatization

1 reference

12 December 2020

Arimidex (ZD1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers

1 reference

12 December 2020

Clinical efficacy and endocrine activity of vorozole in postmenopausal breast cancer patients. Results of a multicentric phase II study

1 reference

12 December 2020

Aromatase inhibition by R 76713: experimental and clinical pharmacology

1 reference

12 December 2020

Isolation of a full-length cDNA insert encoding human aromatase system cytochrome P-450 and its expression in nonsteroidogenic cells

1 reference

12 December 2020

A new irreversible aromatase inhibitor, 6-methylenandrosta-1,4-diene-3,17-dione (FCE 24304): antitumor activity and endocrine effects in rats with DMBA-induced mammary tumors

1 reference

12 December 2020

Correlation of breast tumour aromatase activity and response to aromatase inhibition with aminoglutethimide

1 reference

12 December 2020

Relations between sex hormones, sex hormone binding globulin, insulin-like growth factor-I and insulin-like growth factor binding protein-1 in post-menopausal breast cancer patients.

1 reference

12 December 2020

Determination of aromatase cytochrome P450 messenger ribonucleic acid in human breast tissue by competitive polymerase chain reaction amplification

1 reference

12 December 2020

The Effect of an Aromatase Inhibitor, 4-Hydroxy-4-Androstene- 3,17-Dione, On Estrogen-Dependent Processes in Reproduction and Breast Cancer11

1 reference

12 December 2020

Breast Cancer Prevention Trial shows major benefit, some risk

1 reference

12 December 2020

Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor.

1 reference

12 December 2020

6-Methylenandrosta-1,4-diene-3,17-dione (FCE 24304): a new irreversible aromatase inhibitor

1 reference

12 December 2020

The efficacy of CGS 20267 in suppressing estrogen biosynthesis in patients with advanced stage breast cancer

1 reference

12 December 2020

Pharmacology of vorozole

1 reference

12 December 2020

Stereochemistry of the functional group determines the mechanism of aromatase inhibition by 6-bromoandrostenedione

1 reference

12 December 2020

Analogues of 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione as selective inhibitors of aromatase: derivatives with variable 1-alkyl and 3-alkyl substituents.

1 reference

12 December 2020

Vorozole (Rivizor): an active and well tolerated new aromatase inhibitor for the treatment of advanced breast cancer patients with prior tamoxifen exposure. Investigational Drug Branch of the European Organization for Research and Treatment of Cance

1 reference

12 December 2020

Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in healthy postmenopausal women

1 reference

12 December 2020

Detection of intratumoral aromatase in breast carcinomas. An immunohistochemical study with clinicopathologic correlation

1 reference

12 December 2020

Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor

1 reference

12 December 2020

ARIMIDEX: a new oral, once-a-day aromatase inhibitor.

1 reference

12 December 2020

Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen.

1 reference

12 December 2020

Biological aromatization of steroids

1 reference

12 December 2020

Aminoglutethimide in the treatment of advanced postmenopausal breast cancer

1 reference

12 December 2020

Mechanistic studies on aromatase and related C-C bond cleaving P-450 enzymes

1 reference

12 December 2020

Expression of aromatase cytochrome P-450 in premenopausal and postmenopausal human ovaries: an immunocytochemical study.

1 reference

12 December 2020

Stable expression of human aromatase complementary DNA in mammalian cells: a useful system for aromatase inhibitor screening

1 reference

12 December 2020

Anastrozole--a new generation in aromatase inhibition: clinical pharmacology

1 reference

12 December 2020

Arimidex: a potent and selective fourth-generation aromatase inhibitor

1 reference

12 December 2020

R 76713, a new specific non-steroidal aromatase inhibitor

1 reference

12 December 2020

Formestane in the treatment of advanced postmenopausal breast cancer.

1 reference

12 December 2020

Inhibition of Peripheral Aromatization of Androstenedione to Estrone in Postmenopausal Women with Breast Cancer Using Δ1Testololactone*

1 reference

12 December 2020

The formation of estrogens by central neuroendocrine tissues

1 reference

12 December 2020

R 76713 and enantiomers: selective, nonsteroidal inhibitors of the cytochrome P450-dependent oestrogen synthesis

1 reference

12 December 2020

Aromatase inhibitors as potential cancer chemopreventives.

1 reference

12 December 2020

Regulation of Aromatase Activity of Stromal Cells Derived from Human Adipose Tissue*

1 reference

12 December 2020

Inhibition of the in vivo conversion of androstenedione to estrone by the aromatase inhibitor vorozole in healthy postmenopausal women

1 reference

12 December 2020

Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer

1 reference

12 December 2020

Fadrozole hydrochloride in postmenopausal patients with metastatic breast carcinoma

1 reference

12 December 2020

4-hydroxyandrostenedione: a new treatment for postmenopausal patients with breast cancer

1 reference

12 December 2020

Therapeutic effects of the aromatase inhibitor fadrozole hydrochloride in advanced breast cancer

1 reference

12 December 2020

The mechanism of pancreatic secretion

1 reference

12 December 2020

Letrozole, a new oral non-steroidal aromastase inhibitor in treating postmenopausal patients with advanced breast cancer. A pilot study

1 reference

12 December 2020

Intratesticular site of aromatase activity and possible function of testicular estradiol.

1 reference

12 December 2020

Relationship between tumour aromatase activity, tumour characteristics and response to therapy

1 reference

12 December 2020

Endocrine, pharmacokinetic and clinical studies of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione ('pyridoglutethimide') in postmenopausal breast cancer patients

1 reference

12 December 2020

10.2165/00003495-199958020-00003

Identifiers

DOI

1 reference

Dimensions Publication ID

28 July 2017

1044108615

0 references

1 reference